CytoDyn Inc. business relationships
Companies named in CytoDyn Inc.’s 10-K filed 2026-08-31, and public companies whose annual reports name CytoDyn Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in CytoDyn Inc.’s annual report 4
“On June 4, 2026, Natera, Inc. and CytoDyn jointly announced a strategic collaboration to advance ctDNA-guided development and molecular response analysis in metastatic colorectal cancer.” SEC filing
“To the extent that such milestone payments and royalties are not timely made, under their respective agreements, Progenics has certain repurchase rights relating to the assets sold to us, and AbbVie has certain termination rights relating to our license of leronlimab under the PDL License.” SEC filing
“protection of our rights in our intellectual property portfolio, including our ability to maintain our license agreement with AbbVie,” SEC filing
“License Agreement between CytoDyn Inc. and Lonza Sales AG dated July 29, 2015” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.